Open Payments

CPMC-R.K. DAVIES MEDICAL CENTER

Type
Teaching hospital
Where
San Francisco, CA
Medicare CCN
050008
Received
$1,865,721 in 79 records, 2024 ($1,127,132 general, $738,589 research)
Source
CMS Open Payments search ↗

By year

Program yearKindRecordsAmount
2024General payment7$1,127,132
2024Research payment72$738,589

By company

CompanyRecordsAmountYears
Lilly USA, LLC3$1,115,9202024
Abbott Laboratories12$220,8972024
ABBVIE INC.9$144,7582024
Genentech, Inc.7$143,1992024
Biogen, Inc.2$84,5752024
Eli Lilly and Company5$50,2462024
Gilead Sciences, Inc.7$46,0502024
GENZYME CORPORATION4$35,5842024
AtriCure, Inc.5$8,2422024
Jenavalve Technology, Inc.1$6,7122024
Siemens Medical Solutions USA, Inc.2$4,0002024
Immunocore Limited4$1,4582024
CSL Behring2$1,1652024
ARGENX US, INC.13$9442024
Novocure Inc.1$8142024
UCB SA1$6522024
Tandem Diabetes Care, Inc.1$5002024

By nature of payment

NatureRecordsAmount
Grant5$1,119,920
Research payment72$738,589
Compensation for services other than consulting, including serving as faculty or as a speaker at a v2$7,212

Records

DateCompanyAmountNatureFormProductStudyYear
2024-12-30ABBVIE INC.$5,821Research paymentCash or cash equivalentA Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-C2024
2024-12-27Abbott Laboratories$30,250Research paymentCash or cash equivalentFreeStyle Libre 2 Device, DIABETES CAREA PILOT STUDY COMPARING LIFESTYLE INTERVENTIONS AND INTERMITTENT CONTINUOUS GLUCOSE MONITORING IN PR2024
2024-12-20Genentech, Inc.$22,661Research paymentCash or cash equivalentOcrevus Biological, ImmunologyA PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS2024
2024-12-19Immunocore Limited$364Research paymentCash or cash equivalentKIMMTRAK Drug, OncologyA Phase II Randomized, Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Compared with Investigators2024
2024-12-05ABBVIE INC.$23,765Research paymentCash or cash equivalentA Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-C2024
2024-12-05Tandem Diabetes Care, Inc.$500Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentt:slim X2 Insulin Pump with Control-IQ Device, Endocrinology2024
2024-12-01ARGENX US, INC.$70Research paymentCash or cash equivalentVYVGART HYTRULO Drug, NeurologyA Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless 2024
2024-11-21Eli Lilly and Company$2,603Research paymentIn-kind items and servicesA STUDY OF REMTERNETUG VERSUS PLACEBO IN EARLY ALZHEIMER'S DISEASE PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DEC2024
2024-11-18Abbott Laboratories$101,157Research paymentCash or cash equivalentAGILIS Device, ELECTROPHYSIOLOGYVOLT-AF IDE Clinical Study2024
2024-11-13Gilead Sciences, Inc.$3,614Research paymentCash or cash equivalentA 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar o2024
2024-11-13Gilead Sciences, Inc.$1,530Research paymentCash or cash equivalentA 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar o2024
2024-11-12Abbott Laboratories$2,023Research paymentIn-kind items and servicesFreeStyle Libre 3 Device, DIABETES CAREAssessing the Glycemic Impact of an Online Lifestyle Intervention using CGM (Continuous Glucose Monitoring)2024
2024-11-11Abbott Laboratories$4,423Research paymentCash or cash equivalentTRICLIP Device, STRUCTURAL HEARTClinical Trial to Evaluate Cardiovascular Outcomes In Patients Treated With the Tricuspid Valve Repair System Pivotal2024
2024-11-08Genentech, Inc.$1,694Research paymentCash or cash equivalentOcrevus Biological, ImmunologyA PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS2024
2024-11-08Eli Lilly and Company$9Research paymentIn-kind items and servicesA PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF PIRTOBRUTINIB (LOXO-305) VERSUS IBRUTINIB IN PATIENTS WITH CHRONIC LYMPHOCYTIC2024
2024-11-07ABBVIE INC.$5,665Research paymentCash or cash equivalentA Phase 3, Randomized, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination With R-CHOP Compar2024
2024-11-04Genentech, Inc.$10,266Research paymentCash or cash equivalentOcrevus Biological, ImmunologyA PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS2024
2024-11-01Gilead Sciences, Inc.$6,297Research paymentCash or cash equivalentLivdelzi Drug, INFLAMAn Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects With Primary Biliary Cho2024
2024-11-01ARGENX US, INC.$70Research paymentCash or cash equivalentVYVGART HYTRULO Drug, NeurologyA Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless 2024
2024-10-23Abbott Laboratories$3,420Research paymentIn-kind items and servicesFreeStyle Libre 3 Device, DIABETES CAREAssessing the Glycemic Impact of an Online Lifestyle Intervention using CGM (Continuous Glucose Monitoring)2024
2024-10-16Lilly USA, LLC$600,000GrantCash or cash equivalent2024
2024-10-16Lilly USA, LLC$31,632GrantCash or cash equivalent2024
2024-10-03ABBVIE INC.$12,771Research paymentCash or cash equivalentA Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-C2024
2024-10-01ARGENX US, INC.$70Research paymentCash or cash equivalentVYVGART HYTRULO Drug, NeurologyA Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless 2024
2024-09-19Immunocore Limited$364Research paymentCash or cash equivalentKIMMTRAK Drug, OncologyA Phase II Randomized, Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Compared with Investigators2024
2024-09-16GENZYME CORPORATION$22,060Research paymentCash or cash equivalentA Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Pa2024
2024-09-06Gilead Sciences, Inc.$15,133Research paymentCash or cash equivalentA 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar o2024
2024-09-04ABBVIE INC.$22,011Research paymentCash or cash equivalentA Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-C2024
2024-09-04ABBVIE INC.$17,267Research paymentCash or cash equivalentStudy Assessing Activity of Intravenous (IV) ABBV-383 Monotherapy Versus Standard Available Therapies in Adult Participa2024
2024-09-01ARGENX US, INC.$70Research paymentCash or cash equivalentVYVGART HYTRULO Drug, NeurologyA Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless 2024
2024-08-26Lilly USA, LLC$484,288GrantCash or cash equivalent2024
2024-08-21Siemens Medical Solutions USA, Inc.$1,500GrantCash or cash equivalent2024
2024-08-14Abbott Laboratories$7,078Research paymentCash or cash equivalentTRICLIP Device, STRUCTURAL HEARTClinical TRIal to EvaLUate Cardiovascular OutcoMes IN PAtients Treated with the Tricuspid ValvE Repair System Pivotal2024
2024-08-07Abbott Laboratories$51,246Research paymentCash or cash equivalentAGILIS Device, ELECTROPHYSIOLOGYVOLT-AF IDE2024
2024-08-02ABBVIE INC.$7,227Research paymentCash or cash equivalentA Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-C2024
2024-08-01Gilead Sciences, Inc.$13,612Research paymentCash or cash equivalentLivdelzi Drug, INFLAMAn Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects With Primary Biliary Cho2024
2024-08-01ARGENX US, INC.$70Research paymentCash or cash equivalentVYVGART HYTRULO Drug, NeurologyA Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless 2024
2024-07-18Genentech, Inc.$46,484Research paymentCash or cash equivalentOcrevus Biological, ImmunologyA PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS2024
2024-07-05ABBVIE INC.$32,961Research paymentCash or cash equivalentA Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-C2024
2024-07-01ARGENX US, INC.$70Research paymentCash or cash equivalentVYVGART HYTRULO Drug, NeurologyA Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless 2024
2024-07-01ARGENX US, INC.$70Research paymentCash or cash equivalentVYVGART HYTRULO Drug, NeurologyA Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless 2024
2024-06-13Immunocore Limited$364Research paymentCash or cash equivalentKIMMTRAK Drug, OncologyA Phase II Randomized, Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Compared with Investigators2024
2024-06-12Jenavalve Technology, Inc.$6,712Compensation for services other than consulting, including serving as faculty or as a speaker at a v (2 payments)Cash or cash equivalent2024
2024-06-07Gilead Sciences, Inc.$2,560Research paymentCash or cash equivalentA 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar o2024
2024-05-21Gilead Sciences, Inc.$3,301Research paymentCash or cash equivalentLivdelzi Drug, INFLAMAn Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects With Primary Biliary Cho2024
2024-05-08Abbott Laboratories$7,015Research paymentCash or cash equivalentTRICLIP Device, STRUCTURAL HEARTClinical Trial to Evaluate Cardiovascular Outcomes In Patients Treated With the Tricuspid Valve Repair System Pivotal2024
2024-05-01Siemens Medical Solutions USA, Inc.$2,500GrantCash or cash equivalentVarian Ethos Treatment Planning Device, Oncology2024
2024-05-01ARGENX US, INC.$70Research paymentCash or cash equivalentVYVGART HYTRULO Drug, NeurologyA Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless 2024
2024-04-30AtriCure, Inc.$2,392Research paymentCash or cash equivalentATRICLIP LAA EXCLUSION SYSTEM Device, CARDIOVASCULARPIVOTAL STUDY OF A DUAL EPICARDIAL AND ENDOCARDIAL PROCEDURE DEEP APPROACH FOR TREATMENT OF SUBJECTS WITH PERSISTENT OR 2024
2024-04-18Genentech, Inc.$10,224Research paymentCash or cash equivalentOcrevus Biological, ImmunologyA PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS2024
2024-04-16Abbott Laboratories$10,000Research paymentCash or cash equivalentAGILIS Device, ELECTROPHYSIOLOGYVOLT-AF IDE Clinical Study2024
2024-04-12Abbott Laboratories$50Research paymentIn-kind items and servicesAGILIS Device, ELECTROPHYSIOLOGYVOLT-AF IDE Clinical Study2024
2024-04-12Abbott Laboratories$15Research paymentIn-kind items and servicesAGILIS Device, ELECTROPHYSIOLOGYVOLT-AF IDE Clinical Study2024
2024-04-10Eli Lilly and Company$24,178Research paymentCash or cash equivalentA PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF PIRTOBRUTINIB (LOXO-305) VERSUS IBRUTINIB IN PATIENTS WITH CHRONIC LYMPHOCYTIC2024
2024-04-01ARGENX US, INC.$70Research paymentCash or cash equivalentVYVGART HYTRULO Drug, NeurologyA Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless 2024
2024-03-12Eli Lilly and Company$22,581Research paymentCash or cash equivalentA STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE2024
2024-03-07ABBVIE INC.$17,267Research paymentCash or cash equivalentA Phase 3, Multicenter, Randomized, Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with 2024
2024-03-06AtriCure, Inc.$850Research paymentCash or cash equivalentATRICLIP LAA EXCLUSION SYSTEM Device, CARDIOVASCULARPIVOTAL STUDY OF A DUAL EPICARDIAL AND ENDOCARDIAL PROCEDURE DEEP APPROACH FOR TREATMENT OF SUBJECTS WITH PERSISTENT OR 2024
2024-03-06AtriCure, Inc.$500Research paymentCash or cash equivalentATRICLIP LAA EXCLUSION SYSTEM Device, CARDIOVASCULARPIVOTAL STUDY OF A DUAL EPICARDIAL AND ENDOCARDIAL PROCEDURE DEEP APPROACH FOR TREATMENT OF SUBJECTS WITH PERSISTENT OR 2024
2024-03-06AtriCure, Inc.$500Research paymentCash or cash equivalentATRICLIP LAA EXCLUSION SYSTEM Device, CARDIOVASCULARPIVOTAL STUDY OF A DUAL EPICARDIAL AND ENDOCARDIAL PROCEDURE DEEP APPROACH FOR TREATMENT OF SUBJECTS WITH PERSISTENT OR 2024
2024-03-01ARGENX US, INC.$70Research paymentCash or cash equivalentVYVGART HYTRULO Drug, NeurologyA Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless 2024
2024-02-26GENZYME CORPORATION$6,504Research paymentCash or cash equivalentA Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR4432024
2024-02-14CSL Behring$72Research paymentIn-kind items and servicesA Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody2024
2024-02-13CSL Behring$1,093Research paymentCash or cash equivalentA Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody2024
2024-02-12Abbott Laboratories$4,219Research paymentCash or cash equivalentTRICLIP Device, STRUCTURAL HEARTClinical Trial to Evaluate Cardiovascular Outcomes In Patients Treated With the Tricuspid Valve Repair System Pivotal2024
2024-02-01Novocure Inc.$814Research paymentCash or cash equivalentEF-28 Engot -ov50/ INNOVATE-3: Pivotal, Randomized, Open-Label Study of Tumor Treating Fields (TTFields, 200kHz) Concomi2024
2024-02-01ARGENX US, INC.$104Research paymentCash or cash equivalentVYVGART HYTRULO Drug, NeurologyA Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless 2024
2024-02-01ARGENX US, INC.$70Research paymentCash or cash equivalentVYVGART HYTRULO Drug, NeurologyA Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless 2024
2024-01-29Immunocore Limited$364Research paymentCash or cash equivalentKIMMTRAK Drug, OncologyA Phase II Randomized, Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Compared with Investigators2024
2024-01-22GENZYME CORPORATION$6,625Research paymentCash or cash equivalentA Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR4432024
2024-01-18Genentech, Inc.$6,552Research paymentCash or cash equivalentOcrevus Biological, ImmunologyA PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS2024
2024-01-16UCB SA$652Research paymentCash or cash equivalentZilbrysq Biological, NeurologyPhase 3, Multicenter, Open-Label Extension Study of Zilucoplan in Subjects with Generalized Myasthenia Gravis2024
2024-01-11Genentech, Inc.$45,318Research paymentCash or cash equivalentOcrevus Biological, ImmunologyA PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS2024
2024-01-09Eli Lilly and Company$874Research paymentIn-kind items and servicesA STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE2024
2024-01-05Biogen, Inc.$20,264Research paymentCash or cash equivalentQALSODY Drug, NeurologyA Phase 3 Randomized, Placebo-Controlled Trial of Tofersen in Adults with a Confirmed Mutation in the Superoxide Dismuta2024
2024-01-04AtriCure, Inc.$4,000Research paymentCash or cash equivalentATRICURE CRYOICE CRYOSPHERE CRYOABLATION SYSTEM Device, CARDIOVASCULARATRICURE INCORAF RETRO2024
2024-01-03Biogen, Inc.$64,311Research paymentCash or cash equivalentADUHELM Biological, NeurologyA Phase 3b/4 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Verify the Clinical Bene2024
2024-01-03GENZYME CORPORATION$395Research paymentCash or cash equivalentA Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR4432024
2024-01-01ARGENX US, INC.$70Research paymentCash or cash equivalentVYVGART HYTRULO Drug, NeurologyA Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless 2024

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

San Francisco CountySan Francisco city

County outline, the place (blue), the tract (orange) and the ZIP center (dot).

In San Francisco, CA, county San Francisco County, CA, state California; placed by its city name.

MeasurePlace (city or town)
San Francisco, CA
County
San Francisco County, CA
State
California
Population B01003830,235830,23539,287,377
Population, 2020 census P1873,965873,96539,538,223
Median age B0100240.040.037.9
Under 18 B0100113.7%13.7%22.0%
65 and over B0100117.6%17.6%15.7%
Households B11001363,970363,97013,548,091
Foreign born B0500234.0%34.0%27.0%
Median household income B19013$140,970$140,970$99,122
Median family income B19113$171,141$171,141$113,346
Per capita income B19301$92,289$92,289$49,513
Poverty rate B1700111.2%11.2%12.0%
Unemployment rate B230256.1%6.1%6.6%
Civilian labor force B23025507,262507,26220,068,466
Mean commute (minutes) B0801330.430.428.7
Bachelor's degree or higher B1500360.3%60.3%37.1%
Housing units B25001414,602414,60214,644,735
Owner-occupied B2500338.2%38.2%55.9%
Renters B2500361.8%61.8%44.1%
Median home value B25077$1,394,500$1,394,500$734,700
Median gross rent B25064$2,476$2,476$2,036
White, not Hispanic B0300236.8%36.8%33.8%
Black B030024.7%4.7%5.2%
Hispanic or Latino B0300216.2%16.2%40.2%
Asian B0300234.9%34.9%15.3%
American Indian and Alaska Native B030020.2%0.2%0.3%

Economy now FRED unemployment 5.1% in Sep 2026 (5.5% a year earlier); per capita personal income $90,957 in 2025, up 30% in five years (+4.3% after inflation); Unemployment rate: 5.5% in Sep 2016 to 5.1% in Sep 2026; low 3.8%, high 16.1% the state; Source: FRED, Federal Reserve Bank of St. Louis.

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in San Francisco, CA.

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.